AEBERSOLD, P., C. HYATT, S. JOHNSON, K. HINES, L. KORCAK, M. SANDERS, M.
LOTZE, S. TOPALIAN, J. YANG, und S. A. ROSENBERG (1991):
Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with cli-nical response.
J. Natl. Cancer Inst. 83: 932-937.
ALEXANDER-MILLER, M. A., G. R. LEGGATT, und J. A. BERZOFSKY (1996):
Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adopti-ve immunotherapy.
Proc. Natl. Acad. Sci. U. S. A 93: 4102-4107.
ALTMAN, J. D., P. A. MOSS, P. J. GOULDER, D. H. BAROUCH, M. G. MCHEYZER-WILLIAMS, J. I. BELL, A. J. MCMICHAEL, und M. M. DAVIS (1996):
Phenotypic analysis of antigen-specific T lymphocytes.
Science 274: 94-96.
APPLEMAN, L. J., und V. A. BOUSSIOTIS (2003):
T cell anergy and costimulation.
Immunol. Rev. 192: 161-180.
ASHLEY, D. M., B. FAIOLA, S. NAIR, L. P. HALE, D. D. BIGNER, und E. GILBOA (1997):
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.
J. Exp. Med. 186: 1177-1182.
BANCHEREAU, J., und R. M. STEINMAN (1998):
Dendritic cells and the control of immunity.
Nature 392: 245-252.
BANCHEREAU, J., und A. K. PALUCKA (2005):
Dendritic cells as therapeutic vaccines against cancer.
Nat. Rev. Immunol. 5: 296-306.
BARKER, C. F., und R. E. BILLINGHAM (1977):
Immunologically privileged sites.
Adv. Immunol. 25: 1-54.
BECKER, F. F., D. STILLMAN, und S. SELL (1977):
Serum alpha-fetoprotein in a mouse strain (C3H-Avy fB) with spontaneous hepatocellular carcinomas.
Cancer Res. 37: 870-872.
BEDNAREK, M. A., S. Y. SAUMA, M. C. GAMMON, G. PORTER, S. TAMHANKAR, A. R.
WILLIAMSON, und H. J. ZWEERINK (1991):
The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellu-lar loading of HLA-A2.
J. Immunol. 147: 4047-4053.
BERGWELT-BAILDON, M. S., R. H. VONDERHEIDE, B. MAECKER, N. HIRANO, K. S.
ANDERSON, M. O. BUTLER, Z. XIA, W. Y. ZENG, K. W. WUCHERPFENNIG, L. M.
NADLER, und J. L. SCHULTZE (2002):
Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical applica-tion.
Blood 99: 3319-3325.
BOON, T., A. VAN PEL, E. DE PLAEN, P. CHOMEZ, C. LURQUIN, J. P. SZIKORA, C.
SIBILLE, B. MARIAME, E. B. VAN DEN, B. LETHE, und . (1989):
Genes coding for T-cell-defined tum transplantation antigens: point mutations, antigenic peptides, and subgenic expression.
Cold Spring Harb. Symp. Quant. Biol. 54 Pt 1: 587-596.
BOON, T., T. F. GAJEWSKI, und P. G. COULIE (1995):
From defined human tumor antigens to effective immunization?
Immunol. Today 16: 334-336.
BOON, A. C., E. FRINGUELLI, Y. M. GRAUS, R. A. FOUCHIER, K. SINTNICOLAAS, A.
M. IORIO, G. F. RIMMELZWAAN, und A. D. OSTERHAUS (2002):
Influenza A virus specific T cell immunity in humans during aging.
Virology 299: 100-108.
BOON, A. C., G. DE MUTSERT, R. A. FOUCHIER, K. SINTNICOLAAS, A. D. OSTER-HAUS, und G. F. RIMMELZWAAN (2004):
Preferential HLA usage in the influenza virus-specific CTL response.
J. Immunol. 172: 4435-4443.
BOSMA, G. C., R. P. CUSTER, und M. J. BOSMA (1983):
A severe combined immunodeficiency mutation in the mouse.
Nature 301: 527-530.
BOUVIER, M. (2003):
Accessory proteins and the assembly of human class I MHC molecules: a molecular and structural perspective.
Mol. Immunol. 39: 697-706.
BRENTJENS, R. J., J. B. LATOUCHE, E. SANTOS, F. MARTI, M. C. GONG, C. LYDDA-NE, P. D. KING, S. LARSON, M. WEISS, I. RIVIERE, und M. SADELAIN (2003):
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
Nat. Med. 9: 279-286.
BRETSCHER, P., und M. COHN (1970):
A theory of self-nonself discrimination.
Science 169: 1042-1049.
BRODIE, S. J., B. K. PATTERSON, D. A. LEWINSOHN, K. DIEM, D. SPACH, P. D.
GREENBERG, S. R. RIDDELL, und L. COREY (2000):
HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV rep-lication and cell death.
J. Clin. Invest 105: 1407-1417.
BROWN, J. H., T. S. JARDETZKY, J. C. GORGA, L. J. STERN, R. G. URBAN, J. L.
STROMINGER, und D. C. WILEY (1993):
Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.
Nature 364: 33-39.
BRUNNER, K. T., J. MAUEL, J. C. CEROTTINI, und B. CHAPUIS (1968):
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled alloge-neic target cells in vitro; inhibition by isoantibody and by drugs.
Immunology 14: 181-196.
BRYANT, P., und H. PLOEGH (2004):
Class II MHC peptide loading by the professionals.
Curr. Opin. Immunol. 16: 96-102.
BURNET, F. M. (1970):
The concept of immunological surveillance.
Prog. Exp. Tumor Res. 13: 1-27.
BUTTERFIELD, L. H., A. KOH, W. MENG, C. M. VOLLMER, A. RIBAS, V. DISSETTE, E.
LEE, J. A. GLASPY, W. H. MCBRIDE, und J. S. ECONOMOU (1999):
Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.
Cancer Res. 59: 3134-3142.
BUTTERFIELD, L. H., W. S. MENG, A. KOH, C. M. VOLLMER, A. RIBAS, V. B. DISSET-TE, K. FAULL, J. A. GLASPY, W. H. MCBRIDE, und J. S. ECONOMOU (2001):
T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein.
J. Immunol. 166: 5300-5308.
BUTTERFIELD, L. H., A. RIBAS, W. S. MENG, V. B. DISSETTE, S. AMARNANI, H. T.
VU, E. SEJA, K. TODD, J. A. GLASPY, W. H. MCBRIDE, und J. S. ECONOMOU (2003):
T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.
Clin. Cancer Res. 9: 5902-5908.
BUTTERFIELD, L. H. (2004):
Immunotherapeutic strategies for hepatocellular carcinoma.
Gastroenterology 127: S232-S241.
CELLA, M., F. SALLUSTO, und A. LANZAVECCHIA (1997):
Origin, maturation and antigen presenting function of dendritic cells.
Curr. Opin. Immunol. 9: 10-16.
CHAPUT, N., J. TAIEB, F. ANDRE, und L. ZITVOGEL (2005):
The potential of exosomes in immunotherapy.
Expert. Opin. Biol. Ther. 5: 737-747.
CHEN, L., S. ASHE, W. A. BRADY, I. HELLSTROM, K. E. HELLSTROM, J. A. LEDBET-TER, P. MCGOWAN, und P. S. LINSLEY (1992):
Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte mole-cules CD28 and CTLA-4.
Cell 71: 1093-1102.
CHEN, H., J. O. EGAN, und J. F. CHIU (1997a):
Regulation and activities of alpha-fetoprotein.
Crit Rev. Eukaryot. Gene Expr. 7: 11-41.
CHEN, Y. T., M. J. SCANLAN, U. SAHIN, O. TURECI, A. O. GURE, S. TSANG, B. WILLI-AMSON, E. STOCKERT, M. PFREUNDSCHUH, und L. J. OLD (1997b):
A testicular antigen aberrantly expressed in human cancers detected by autologous anti-body screening.
Proc. Natl. Acad. Sci. U. S. A 94: 1914-1918.
CHEN, C. H., G. J. CHEN, H. S. LEE, G. T. HUANG, P. M. YANG, L. J. TSAI, D. S.
CHEN, und J. C. SHEU (2001):
Expressions of cancer-testis antigens in human hepatocellular carcinomas.
Cancer Lett. 164: 189-195.
CHICZ, R. M., R. G. URBAN, W. S. LANE, J. C. GORGA, L. J. STERN, D. A. VIGNALI, und J. L. STROMINGER (1992):
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Nature 358: 764-768.
COLEY, W. B. (1893):
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases.
Clin. Orthop. Relat Res. 3-11.
COMANS-BITTER, W. M., R. DE GROOT, B. R. VAN DEN, H. J. NEIJENS, W. C. HOP, K. GROENEVELD, H. HOOIJKAAS, und J. J. VAN DONGEN (1997):
Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations.
J. Pediatr. 130: 388-393.
COX, A. L., J. SKIPPER, Y. CHEN, R. A. HENDERSON, T. L. DARROW, J. SHABANO-WITZ, V. H. ENGELHARD, D. F. HUNT, und C. L. SLINGLUFF, Jr. (1994):
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.
Science 264: 716-719.
CROWLEY, N. J., C. E. VERVAERT, und H. F. SEIGLER (1992):
Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells.
Cancer Res. 52: 394-399.
CURTSINGER, J. M., C. S. SCHMIDT, A. MONDINO, D. C. LINS, R. M. KEDL, M. K.
JENKINS, und M. F. MESCHER (1999):
Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.
J. Immunol. 162: 3256-3262.
DARNELL, R. B., und J. B. POSNER (2003):
Observing the invisible: successful tumor immunity in humans.
Nat. Immunol. 4: 201-
DE PLAEN, E., K. ARDEN, C. TRAVERSARI, J. J. GAFORIO, J. P. SZIKORA, C. DE SMET, F. BRASSEUR, B. P. VAN DER, B. LETHE, C. LURQUIN, und . (1994):
Structure, chromosomal localization, and expression of 12 genes of the MAGE family.
Immunogenetics 40: 360-369.
DE SMET, C., O. DE BACKER, I. FARAONI, C. LURQUIN, F. BRASSEUR, und T. BOON (1996):
The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide de-methylation.
Proc. Natl. Acad. Sci. U. S. A 93: 7149-7153.
DE VISSER, K. E., T. N. SCHUMACHER, und A. M. KRUISBEEK (2003):
CD8+ T cell tolerance and cancer immunotherapy.
J. Immunother. 26: 1-11.
DEL MAZO, J., G. PRANTERA, M. TORRES, und M. FERRARO (1994):
DNA methylation changes during mouse spermatogenesis.
Chromosome. Res. 2: 147-152.
DENKBERG, G., C. J. COHEN, D. SEGAL, A. F. KIRKIN, und Y. REITER (2000):
Recombinant human single-chain MHC-peptide complexes made from E. coli By in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor asso-ciated antigens.
Eur. J. Immunol. 30: 3522-3532.
DRAKE, C. G., E. JAFFEE, und D. M. PARDOLL (2006):
Mechanisms of immune evasion by tumors.
Adv. Immunol. 90: 51-81.
DRANOFF, G., E. JAFFEE, A. LAZENBY, P. GOLUMBEK, H. LEVITSKY, K. BROSE, V.
JACKSON, H. HAMADA, D. PARDOLL, und R. C. MULLIGAN (1993):
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Proc. Natl. Acad. Sci. U. S. A 90: 3539-3543.
DUDLEY, M. E., J. R. WUNDERLICH, P. F. ROBBINS, J. C. YANG, P. HWU, D. J.
SCHWARTZENTRUBER, S. L. TOPALIAN, R. SHERRY, N. P. RESTIFO, A. M. HUBICKI, M. R. ROBINSON, M. RAFFELD, P. DURAY, C. A. SEIPP, L. ROGERS-FREEZER, K. E.
MORTON, S. A. MAVROUKAKIS, D. E. WHITE, und S. A. ROSENBERG (2002):
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science 298: 850-854.
DUDLEY, M. E., und S. A. ROSENBERG (2003):
Adoptive-cell-transfer therapy for the treatment of patients with cancer.
Nat. Rev. Cancer 3: 666-675.
DUNBAR, P. R., G. S. OGG, J. CHEN, N. RUST, B. P. VAN DER, und V. CERUNDOLO (1998):
Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood.
Curr. Biol. 8: 413-416.
DUNN, G. P., A. T. BRUCE, H. IKEDA, L. J. OLD, und R. D. SCHREIBER (2002):
Cancer immunoediting: from immunosurveillance to tumor escape.
Nat. Immunol. 3: 991-998.
DUNN, G. P., L. J. OLD, und R. D. SCHREIBER (2004):
The three Es of cancer immunoediting.
Annu. Rev. Immunol. 22: 329-360.
ENGVALL, E., und P. PERLMAN (1971):
Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G.
Immunochemistry. 8: 871-874.
ESPINOSA, E., J. TABIASCO, D. HUDRISIER, und J. J. FOURNIE (2002):
Synaptic transfer by human gamma delta T cells stimulated with soluble or cellular anti-gens.
J. Immunol. 168: 6336-6343.
ESSEX, M., C. K. GRANT, S. M. COTTER, A. H. SLISKI, und W. D. HARDY, Jr. (1979):
Leukemia specific antigens: FOCMA and immune surveillance.
Haematol. Blood Transfus. 23: 453-486.
FALK, K., O. ROTZSCHKE, S. STEVANOVIC, G. JUNG, und H. G. RAMMENSEE (1991):
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.
Nature 351: 290-296.
FEUERER, M., P. BECKHOVE, L. BAI, E. F. SOLOMAYER, G. BASTERT, I. J. DIEL, C.
PEDAIN, M. OBERNIEDERMAYR, V. SCHIRRMACHER, und V. UMANSKY (2001):
Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow.
Nat. Med. 7: 452-458.
FINN, O. J., K. R. JEROME, R. A. HENDERSON, G. PECHER, N. DOMENECH, J. MA-GARIAN-BLANDER, und S. M. BARRATT-BOYES (1995):
MUC-1 epithelial tumor mucin-based immunity and cancer vaccines.
Immunol. Rev. 145: 61-89.
FISCH, P., M. MALKOVSKY, S. KOVATS, E. STURM, E. BRAAKMAN, B. S. KLEIN, S. D.
VOSS, L. W. MORRISSEY, R. DEMARS, W. J. WELCH, und . (1990):
Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells.
Science 250: 1269-1273.
GABRILOVICH, D. (2004):
Mechanisms and functional significance of tumour-induced dendritic-cell defects.
Nat. Rev. Immunol. 4: 941-952.
GACZYNSKA, M., K. L. ROCK, und A. L. GOLDBERG (1993):
Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by protea-somes.
Nature 365: 264-267.
GAGLIARDI, M. C., G. DE PETRILLO, S. SALEMI, L. BOFFA, M. G. LONGOBARDI, P.
DELLABONA, G. CASORATI, N. TANIGAKI, R. HARRIS, A. LANZAVECCHIA, und . (1995):
Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro.
Int. Immunol. 7: 1741-1752.
GAMREKELASHVILI, J., C. KRUGER, R. VON WASIELEWSKI, M. HOFFMANN, K. M.
HUSTER, D. H. BUSCH, M. P. MANNS, F. KORANGY, und T. F. GRETEN (2007):
Necrotic tumor cell death in vivo impairs tumor-specific immune responses.
J. Immunol. 178: 1573-1580.
GARBOCZI, D. N., D. T. HUNG, und D. C. WILEY (1992):
HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Esche-richia coli and complexed with single antigenic peptides.
Proc. Natl. Acad. Sci. U. S. A 89: 3429-3433.
GARLIE, N. K., A. V. LEFEVER, R. E. SIEBENLIST, B. L. LEVINE, C. H. JUNE, und L. G.
LUM (1999):
T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer.
J. Immunother. 22: 336-345.
GATTINONI, L., C. A. KLEBANOFF, D. C. PALMER, C. WRZESINSKI, K. KERSTANN, Z.
YU, S. E. FINKELSTEIN, M. R. THEORET, S. A. ROSENBERG, und N. P. RESTIFO (2005):
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor effica-cy of adoptively transferred CD8+ T cells.
J. Clin. Invest 115: 1616-1626.
GATTINONI, L., D. J. POWELL, Jr., S. A. ROSENBERG, und N. P. RESTIFO (2006):
Adoptive immunotherapy for cancer: building on success.
Nat. Rev. Immunol. 6: 383-393.
GILEADI, U., H. T. MOINS-TEISSERENC, I. CORREA, B. L. BOOTH, Jr., P. R. DUNBAR, A. K. SEWELL, J. TROWSDALE, R. E. PHILLIPS, und V. CERUNDOLO (1999):
Generation of an immunodominant CTL epitope is affected by proteasome subunit compo-sition and stability of the antigenic protein.
J. Immunol. 163: 6045-6052.
GIRLING, A., J. BARTKOVA, J. BURCHELL, S. GENDLER, C. GILLETT, und J. TAYLOR-PAPADIMITRIOU (1989):
A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal an-tibody SM-3 is selectively exposed in a range of primary carcinomas.
Int. J. Cancer 43: 1072-1076.
GOLD, P., und S. O. FREEDMAN (1965):
DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCI-NOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.
J. Exp. Med. 121: 439-462.
GOLDSTEIN, S. A., und M. F. MESCHER (1986):
Cell-sized, supported artificial membranes (pseudocytes): response of precursor cytotoxic T lymphocytes to class I MHC proteins.
J. Immunol. 137: 3383-3392.
GONG, J., D. CHEN, M. KASHIWABA, und D. KUFE (1997):
Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells.
Nat. Med. 3: 558-561.
GOTCH, F., J. ROTHBARD, K. HOWLAND, A. TOWNSEND, und A. MCMICHAEL (1987):
Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in associa-tion with HLA-A2.
Nature 326: 881-882.
GOTTSCHALK, S., O. L. EDWARDS, U. SILI, M. H. HULS, T. GOLTSOVA, A. R. DAVIS, H. E. HESLOP, und C. M. ROONEY (2003):
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adopti-ve immunotherapy of EBV-associated malignancies.
Blood 101: 1905-1912.
GREENBLATT, M. S., W. P. BENNETT, M. HOLLSTEIN, und C. C. HARRIS (1994):
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pa-thogenesis.
Cancer Res. 54: 4855-4878.
GRETEN, T. F., und E. M. JAFFEE (1999):
Cancer vaccines.
J. Clin. Oncol. 17: 1047-1060.
GRETEN, T. F., F. KORANGY, G. NEUMANN, H. WEDEMEYER, K. SCHLOTE, A. HEL-LER, S. SCHEFFER, D. M. PARDOLL, A. I. GARBE, J. P. SCHNECK, und M. P. MANNS (2002):
Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.
J. Immunol. Methods 271: 125-135.
GROLL, M., L. DITZEL, J. LOWE, D. STOCK, M. BOCHTLER, H. D. BARTUNIK, und R.
HUBER (1997):
Structure of 20S proteasome from yeast at 2.4 A resolution.
Nature 386: 463-471.
HANSEN, T. H., und D. R. LEE (1997):
Mechanism of class I assembly with beta 2 microglobulin and loading with peptide.
Adv. Immunol. 64: 105-137.
HAQUE, T., P. L. AMLOT, N. HELLING, J. A. THOMAS, P. SWENY, K. ROLLES, A. K.
BURROUGHS, H. G. PRENTICE, und D. H. CRAWFORD (1998):
Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients.
J. Immunol. 160: 6204-6209.
HAQUE, T., G. M. WILKIE, C. TAYLOR, P. L. AMLOT, P. MURAD, A. ILEY, D. DOMBA-GODA, K. M. BRITTON, A. J. SWERDLOW, und D. H. CRAWFORD (2002):
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Lancet 360: 436-442.
HESLOP, H. E., M. K. BRENNER, und C. M. ROONEY (1994):
Donor T cells to treat EBV-associated lymphoma.
N. Engl. J. Med. 331: 679-680.
HILL, F. W., W. R. KLEIN, M. J. HOYER, V. P. RUTTEN, N. KOCK, J. W. KOTEN, P. A.
STEERENBERG, E. J. RUITENBERG, und W. DEN OTTER (1994a):
Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma.
Vet. Immunol. Immunopathol. 41: 19-29.
HILL, F. W., V. P. RUTTEN, M. H. HOYER, W. R. KLEIN, J. W. KOTEN, P. A. STEEREN-BERG, E. J. RUITENSTEEREN-BERG, und W. DEN OTTER (1994b):
Local bacillus Calmette-Guerin therapy for bovine vulval papilloma and carcinoma.
Cancer Immunol. Immunother. 39: 49-52.
HO, W. Y., J. N. BLATTMAN, M. L. DOSSETT, C. YEE, und P. D. GREENBERG (2003):
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.
Cancer Cell 3: 431-437.
HOOGENDOORN, M., J. O. WOLBERS, W. M. SMIT, M. R. SCHAAFSMA, R. M. BARGE, R. WILLEMZE, und J. H. FALKENBURG (2004):
Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
Leukemia 18: 1278-1287.
HOOGENDOORN, M., W. J. OLDE, W. M. SMIT, M. R. SCHAAFSMA, I. JEDEMA, R. M.
BARGE, R. WILLEMZE, und J. H. FALKENBURG (2005):
Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.
Clin. Cancer Res. 11: 5310-5318.
HUANG, Y., und R. L. WANGE (2004):
T cell receptor signaling: beyond complex complexes.
J. Biol. Chem. 279: 28827-28830.
HUNG, K., R. HAYASHI, A. LAFOND-WALKER, C. LOWENSTEIN, D. PARDOLL, und H.
LEVITSKY (1998):
The central role of CD4(+) T cells in the antitumor immune response.
J. Exp. Med. 188: 2357-2368.
HWANG, I., X. SHEN, und J. SPRENT (2003):
Direct stimulation of naive T cells by membrane vesicles from antigen-presenting cells:
distinct roles for CD54 and B7 molecules.
Proc. Natl. Acad. Sci. U. S. A 100: 6670-6675.
JAFFEE, E. M., R. H. HRUBAN, B. BIEDRZYCKI, D. LAHERU, K. SCHEPERS, P. R.
SAUTER, M. GOEMANN, J. COLEMAN, L. GROCHOW, R. C. DONEHOWER, K. D. LIL-LEMOE, S. O'REILLY, R. A. ABRAMS, D. M. PARDOLL, J. L. CAMERON, und C. J. YEO (2001):
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vacci-ne for pancreatic cancer: a phase I trial of safety and immuvacci-ne activation.
J. Clin. Oncol. 19: 145-156.
JAGER, E., Y. T. CHEN, J. W. DRIJFHOUT, J. KARBACH, M. RINGHOFFER, D. JAGER, M. ARAND, H. WADA, Y. NOGUCHI, E. STOCKERT, L. J. OLD, und A. KNUTH (1998):
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
J. Exp. Med. 187: 265-270.
JUNG, T., U. SCHAUER, C. HEUSSER, C. NEUMANN, und C. RIEGER (1993):
Detection of intracellular cytokines by flow cytometry.
J. Immunol. Methods 159: 197-207.
KARBACH, J., C. PAULIGK, A. BENDER, S. GNJATIC, K. FRANZMANN, C. WAHLE, D.
JAGER, A. KNUTH, L. J. OLD, und E. JAGER (2006):
Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Int. J. Cancer 118: 668-674.
KASS, R., J. AGHA, S. BELLONE, M. PALMIERI, S. CANE, E. BIGNOTTI, R. HENRY-TILLMAN, L. HUTCHINS, M. J. CANNON, S. KLIMBERG, und A. D. SANTIN (2003):
In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells.
J. Surg. Res. 112: 189-197.
KAUR, I., S. D. VOSS, R. S. GUPTA, K. SCHELL, P. FISCH, und P. M. SONDEL (1993):
Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells.
J. Immunol. 150: 2046-2055.
KERSHAW, M. H., M. W. TENG, M. J. SMYTH, und P. K. DARCY (2005):
Supernatural T cells: genetic modification of T cells for cancer therapy.
Nat. Rev. Immunol. 5: 928-940.
KHANNA, R., S. BELL, M. SHERRITT, A. GALBRAITH, S. R. BURROWS, L. RAFTER, B.
CLARKE, R. SLAUGHTER, M. C. FALK, J. DOUGLASS, T. WILLIAMS, S. L. ELLIOTT, und D. J. MOSS (1999):
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid or-gan transplant patients with posttransplant lymphoproliferative disease.
Proc. Natl. Acad. Sci. U. S. A 96: 10391-10396.
KHANNA, R., J. TELLAM, J. DURAISWAMY, und L. COOPER (2001):
Immunotherapeutic strategies for EBV-associated malignancies.
Trends Mol. Med. 7: 270-276.
KIM, J. V., J. B. LATOUCHE, I. RIVIERE, und M. SADELAIN (2004):
The ABCs of artificial antigen presentation.
Nat. Biotechnol. 22: 403-410.
KINNUNEN, R.E., T. TALLBERG, H. STENBACK u. S. SARNA (1999):
Equine sarcoid tumour treated by autogenous tumour vaccine Anticancer Res 19, 3367-3374
KIRCHER, M. F., J. R. ALLPORT, E. E. GRAVES, V. LOVE, L. JOSEPHSON, A. H.
LICHTMAN, und R. WEISSLEDER (2003):
In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors.
Cancer Res. 63: 6838-6846.
KIRKWOOD, J. M., M.T. LOTZE und J.M. YASKO (1994):
Current cancer therapeutics
Current Medicine Philadelphia p. 344
KITAO, S., T. YAMADA, T. ISHIKAWA, H. MADARAME, M. FURUICHI, S. NEO, R. TSU-CHIYA, und K. KOBAYASHI (2006):
Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma.
J. Vet. Diagn. Invest 18: 291-295.
KLEBANOFF, C. A., L. GATTINONI, P. TORABI-PARIZI, K. KERSTANN, A. R. CARDO-NES, S. E. FINKELSTEIN, D. C. PALMER, P. A. ANTONY, S. T. HWANG, S. A. ROSEN-BERG, T. A. WALDMANN, und N. P. RESTIFO (2005a):
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity com-pared with effector memory T cells.
Proc. Natl. Acad. Sci. U. S. A 102: 9571-9576.
KLEBANOFF, C. A., H. T. KHONG, P. A. ANTONY, D. C. PALMER, und N. P. RESTIFO (2005b):
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
Trends Immunol. 26: 111-117.
KLEIN, E., G. KLEIN, J. S. NADKARNI, J. J. NADKARNI, H. WIGZELL, und P. CLIFFORD (1967):
Surgace IgM specificity on cells derived from a Burkitt's lymphoma.
Lancet 2: 1068-1070.
KLEIN, W. R., G. E. BRAS, W. MISDORP, P. A. STEERENBERG, W. H. DE JONG, R. H.
TIESJEMA, A. W. KERSJES, und E. J. RUITENBERG (1986):
Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomi-sed clinical trial.
Cancer Immunol. Immunother. 21: 133-140.
KORANGY, F., L. A. ORMANDY, J. S. BLECK, J. KLEMPNAUER, L. WILKENS, M. P.
MANNS, und T. F. GRETEN (2004):
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in he-patocellular carcinoma.
Clin. Cancer Res. 10: 4332-4341.
KUBALL, J., F. W. SCHMITZ, R. H. VOSS, E. A. FERREIRA, R. ENGEL, P. GUILLAUME, S. STRAND, P. ROMERO, C. HUBER, L. A. SHERMAN, und M. THEOBALD (2005):
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
Immunity. 22: 117-129.
KUSMARTSEV, S., und D. I. GABRILOVICH (2006):
Role of immature myeloid cells in mechanisms of immune evasion in cancer.
Cancer Immunol. Immunother. 55: 237-245.
LALVANI, A., R. BROOKES, S. HAMBLETON, W. J. BRITTON, A. V. HILL, und A. J.
MCMICHAEL (1997):
Rapid effector function in CD8+ memory T cells.
J. Exp. Med. 186: 859-865.
LANKAT-BUTTGEREIT, B., und R. TAMPE (2002):
The transporter associated with antigen processing: function and implications in human diseases.
Physiol Rev. 82: 187-204.
LANZAVECCHIA, A., und F. SALLUSTO (2001):
Antigen decoding by T lymphocytes: from synapses to fate determination.
Nat. Immunol. 2: 487-492.
LATOUCHE, J. B., und M. SADELAIN (2000):
Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
Nat. Biotechnol. 18: 405-409.
LEVINE, B. L., J. COTTE, C. C. SMALL, R. G. CARROLL, J. L. RILEY, W. B. BERN-STEIN, D. E. VAN EPPS, R. A. HARDWICK, und C. H. JUNE (1998):
Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costi-mulation.
J. Hematother. 7: 437-448.
LIU, Y. J., H. KANZLER, V. SOUMELIS, und M. GILLIET (2001):
Dendritic cell lineage, plasticity and cross-regulation.
Nat. Immunol. 2: 585-589.
LOWSETH, L. A., N. A. GILLETT, I. Y. CHANG, B. A. MUGGENBURG, und B. B. BO-ECKER (1991):
Detection of serum alpha-fetoprotein in dogs with hepatic tumors.
J. Am. Vet. Med. Assoc. 199: 735-741.
LOZZIO, C. B., und B. B. LOZZIO (1975):
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.
Blood 45: 321-334.
LYNCH, D. H., und R. E. MILLER (1994):
Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.
J. Exp. Med. 179: 31-42.
LYONS, A. B., und C. R. PARISH (1994):
Determination of lymphocyte division by flow cytometry.
J. Immunol. Methods 171: 131-137.
MACARY, P. A., C. T. TOO, und X. DAI (2006):
Targeting tumours by adoptive transfer of immune cells.
Clin. Exp. Pharmacol. Physiol 33: 569-574.
MACKENSEN, A., G. CARCELAIN, S. VIEL, M. C. RAYNAL, H. MICHALAKI, F. TRIEBEL, J. BOSQ, und T. HERCEND (1994):
Direct evidence to support the immunosurveillance concept in a human regressive mela-noma.
J. Clin. Invest 93: 1397-1402.
MACKENSEN, A., B. HERBST, J. L. CHEN, G. KOHLER, C. NOPPEN, W. HERR, G. C.
SPAGNOLI, V. CERUNDOLO, und A. LINDEMANN (2000):
Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells gene-rated in vitro from CD34(+) hematopoietic progenitor cells.
Int. J. Cancer 86: 385-392.
MADDEN, D. R. (1995):
The three-dimensional structure of peptide-MHC complexes.
Annu. Rev. Immunol. 13: 587-622.
MALKOVSKA, V., F. K. CIGEL, N. ARMSTRONG, B. E. STORER, und R. HONG (1992):
Antilymphoma activity of human gamma delta T-cells in mice with severe combined immu-ne deficiency.
Cancer Res. 52: 5610-5616.
MANNERING, S. I., J. L. MCKENZIE, und D. N. HART (1998):
Optimisation of the conditions for generating human DC initiated antigen specific T lym-phocyte lines in vitro.
J. Immunol. Methods 219: 69-83.
MARTIN DE LAS, M. J., J. C. GOMEZ-VILLAMANDOS, J. PEREZ, E. MOZOS, M.
ESTRADO, und A. MENDEZ (1995):
Immunohistochemical evaluation of canine primary liver carcinomas: distribution of alpha-fetoprotein, carcinoembryonic antigen, keratins and vimentin.
Res. Vet. Sci. 59: 124-127.
MAUS, M. V., A. K. THOMAS, D. G. LEONARD, D. ALLMAN, K. ADDYA, K. SCHLIEN-GER, J. L. RILEY, und C. H. JUNE (2002):
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
Nat. Biotechnol. 20: 143-148.
MCMICHAEL, A. J., F. M. GOTCH, G. R. NOBLE, und P. A. BEARE (1983):
Cytotoxic T-cell immunity to influenza.
N. Engl. J. Med. 309: 13-17.
MEDZHITOV, R., und C. A. JANEWAY, Jr. (1997):
Innate immunity: the virtues of a nonclonal system of recognition.
Cell 91: 295-298.
MEIDENBAUER, N., J. MARIENHAGEN, M. LAUMER, S. VOGL, J. HEYMANN, R.
ANDREESEN, und A. MACKENSEN (2003):
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in mela-noma patients.
J. Immunol. 170: 2161-2169.
MITCHELL, M. S. (2002):
Cancer vaccines, a critical review--Part I.
Curr. Opin. Investig. Drugs 3: 140-149.
MITCHELL, M. S., D. DARRAH, D. YEUNG, S. HALPERN, A. WALLACE, J. VOLAND, V.
JONES, und J. KAN-MITCHELL (2002):
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope.
J. Clin. Oncol. 20: 1075-1086.
MIZEJEWSKI, G. J. (1995):
Alpha-fetoprotein signal sequences: a proposed mechanism for subcellular localization and organelle targeting.
J. Theor. Biol. 176: 103-113.
MOHR, S., G. D. LEIKAUF, G. KEITH, und B. H. RIHN (2002):
Microarrays as cancer keys: an array of possibilities.
J. Clin. Oncol. 20: 3165-3175.
MOROZ, A., C. EPPOLITO, Q. LI, J. TAO, C. H. CLEGG, und P. A. SHRIKANT (2004):
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:
comparative evaluation of IL-2, IL-15, and IL-21.
comparative evaluation of IL-2, IL-15, and IL-21.